Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire by Vanga-Bosson, Henriette A et al.
RESEARCH Open Access
Coverage of intermittent prevention treatment
with sulphadoxine-pyrimethamine among
pregnant women and congenital malaria in Côte
d’Ivoire
Henriette A Vanga-Bosson
1, Patrick A Coffie
2,3,4, Serge Kanhon
2, Caroline Sloan
2, Firmin Kouakou
6, Serge P Eholie
5,
Moussa Kone
1, François Dabis
3,4, Hervé Menan
1,7 and Didier K Ekouevi
2,3,4*
Abstract
Background: The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs)
and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan
Africa. Data on IPT-SP coverage and factors associated with placental malaria parasitaemia and low birth weight
(LBW) are scarce in Côte d’Ivoire.
Methods: A multicentre, cross-sectional survey was conducted in Côte d’Ivoire from March to September 2008 at
six urban and semi-urban antenatal clinics. Standardized forms were used to collect the demographic information
and medical histories of women and their offspring. IPT-SP coverage (≥2 doses) as well as placental and congenital
malaria prevalence parasitaemia were estimated. Regression logistics were used to study factors associated with
placental malaria and LBW (birth weight of alive babies < 2,500 grams).
Results: Overall, 2,044 women with a median age of 24 years were included in this study. Among them 1017
(49.8%) received ≥2 doses of IPT-SP and 694 (34.0%) received one dose. A total of 99 mothers (4.8%) had placental
malaria, and of them, four cases of congenital malaria were diagnosed. Factors that protected from maternal
placental malaria parasitaemia were the use of one dose (adjusted odds ratio (aOR), 0.32; 95%CI: 0.19-0.55) or ≥2
doses IPT-SP (aOR: 0.18; 95%CI: 0.10-0.32); the use of ITNs (aOR: 0.47; 95%CI: 0.27-0.82). LBW was associated with
primigravidity and placental malaria parasitaemia.
Conclusion: IPT-SP decreases the rate of placental malaria parasitaemia and has a strong dose effect. Despite
relatively successful IPT-SP coverage in Côte d’Ivoire, substantial commitments from national authorities are
urgently required for such public health campaigns. Strategies, such as providing IPT-SP free of charge and directly
observing treatment, should be implemented to increase the use of IPT-SP as well as other prophylactic methods.
Background
Malaria is a global public health issue especially impor-
tant in Africa, home to more than 70% of all infections
worldwide and 243 million new infections in 2008 [1].
The World Health Organization (WHO) estimates that
one child dies of malaria every 45 seconds in Africa,
accounting for 20% of all childhood deaths in the
malaria endemic region [1,2]. Approximately fifty
million women become pregnant in malaria-endemic
areas each year. Half of these pregnancies are in sub-
Saharan African regions where rates of infection with
Plasmodium falciparum are steady throughout the year
[1,2]. Recent studies have shown that the rate of placen-
tal malaria varied between 6% and 41%, according to
laboratory investigations and type of intervention
initiated [3-6]. The presence of P. falciparum parasites
in intervillous spaces (IVS) resulted in the increase of
maternal morbidity, low birth weight (LBW), and * Correspondence: didier.ekouevi@gmail.com
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leads to severe anaemia in pregnant African women
[10].
Strategies for controlling malaria during pregnancy in
sub-Saharan Africa often include treatment of the dis-
ease and resulting anaemia as well as chemoprophylaxis
[1,11]. Weekly chloroquine was previously used to pre-
vent malaria [1], but it is no longer administered in this
region because of the recent emergence of resistance.
Since 2004, the WHO recommends a more effective
strategy for preventing malaria during pregnancy, which
includes insecticide-treated mosquito nets (ITNs) and
intermittent preventive treatment (IPT) [2,12]. IPT for
pregnant women consists of two doses of sulphadoxine-
pyrimethamine (SP) (1500/75 mg), administered at
scheduled clinic visits at least one month apart, starting
in the second trimester [2]. HIV-infected pregnant
women must take three doses of IPT with SP (IPT-SP)
if they do not already take cotrimoxazole prophylaxis to
prevent opportunistic infections [2]. However, the pro-
portion of pregnant women who receive ≥two doses of
IPT-SP in sub-Saharan Africa remains relatively low, at
rates varying between 3% and 66% [1].
Côte d’Ivoire has the highest prevalence of HIV in
West Africa, at 4.7% [13]. It is also located in a region
where malaria is endemic, with steady rates of P. falci-
parum infection throughout the year. Although Côte
d’Ivoire has implemented the WHO recommendations
for preventing malaria since 2005, this implementation
has never been evaluated and information on the opera-
tional effectiveness of IPT-SP is limited. The objective
of this study was to evaluate the coverage of IPT-SP, the
prevalence of congenital malaria parasitaemia, and to
determine the factors associated with placental malaria
and LBW in six health facilities in Côte d’Ivoire.
Methods
Study sites
A multicenter, cross-sectional survey was conducted in
Côte d’Ivoire between March and September 2008 at six
randomly selected antenatal facilities providing preven-
tion of mother-to-child transmission of HIV (PMTCT)
services. Details of the selection of the facilities have
been presented elsewhere [14].
Briefly, the Ministry of Health provided the list of
health facilities in southern and central Côte d’Ivoire
providing PMTCT services. Overall, 104 facilities were
eligible in November 2006. These PMTCT sites were
located in three types of settings: 41 were in Abidjan, 25
were in other urban areas, and 38 were in semi-urban
areas. Two health facilities from each setting were ran-
domly selected. San Pedro and Bouaké and the two sites
in Abidjan are located in urban areas and Grand-Lahou
and Sassandra are located in semi-urban areas.
Overall, two sites were located in Abidjan (in the dis-
tricts of Yopougon and Koumassi), three in the southern
coastal region (Grand-Lahou, Sassandra, San Pedro), and
one in the centre region (Bouaké, the country’ss e c o n d
largest city). All of the health facilities included in this
study provided PMTCT services.
The climate of Côte d’Ivoire’s coastal and central
regions is tropical with four seasons: two dry and two
rainy seasons. The dry seasons last from December to
April and from August to September. The rainy seasons
last from May to July and from October to November.
Average temperatures in Abidjan range from 21°C to
33°C and malaria infections occur throughout the entire
year. Malaria transmission is endemic to the entire
region in Côte d’Ivoire.
Sample size calculations
The sample size calculation was based on the estimate
of a proportion of placental malaria. In the absence of
data on the prevalence of malaria in Côte d’Ivoire, data
from Ghana which borders Côte d’Ivoire were used. The
prevalence of placental malaria after IPT-SP implemen-
tation was 15% [15]. With a margin of error of ± 2%
using an alpha type-1 error of 5%, at least 1224 preg-
nant women should be included during the study per-
iod, with a minimum of 200 women from each of the
six selected sites.
Study population
Pregnant women who (i) gave birth at any of the six
study clinics during the study period, (ii) gave their ver-
bal informed consent, and (iii) donated placentas for
blood collection were enrolled.
Data collection
In the delivery ward, standardized forms were used to
collect demographic information (age, location, etc.),
medical histories (parity, gravidity, number of antenatal
clinic visits, use of anti-malaria prophylaxis and treat-
ment), and the use of ITNs. This information was
obtained from the patients’ medical charts. Data were
collected on the mother’s pregnancy and the child’s
anthropometric characteristics at birth from the mater-
nity register.
Laboratory investigations
Training
Six pharmacy students working on their dissertations at
the “Unité de Formation et de Recherche des Sciences
Pharmaceutiques d’Abidjan” underwent a two-week
training course conducted by one senior biologist (HVB)
at the delivery ward at the University of Cocody Teach-
ing Hospital. They performed all laboratory tests during
this study period.
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Blood samples were collected from the umbilical cord
immediately after delivery. Specimens from all consent-
ing women who gave birth to live infants during the
study period were obtained. Pharmacy students
extracted 5 mL of blood from the discarded placenta/
umbilical cord after delivery and placed the sample in a
serum-separating tube that was assigned a unique iden-
tifier. These blood samples were used to detect malaria
parasitaemia in peripheral blood and to test for HIV.
Placental blood samples
After the umbilical cord blood samples were collected,
the placenta was placed with the maternal side facing
upward. After cleaning with sterile saline solution, a
healthy paracentric area was incised. Pharmacy students
collected 2 mL of placental blood in sterile EDTA tubes
using this incision method, which involves making a
shallow incision in the maternal side with sterile scissors
and collecting the blood that pools from the IVS.
Neonatal blood samples
Blood samples were collected two hours after birth from
neonates of which their mothers’ placentas were infected
with P. falciparum. Two drops of blood by puncturing
the neonate’s heel with a sterile lancet were collected.
Malaria diagnosis
Rapid Diagnostic Test (RDT) (ACON
® Malaria Plasmo-
dium falciparum, ACON Laboratories, Inc.) was used to
test peripheral and placental blood for malaria parasitae-
mia. ACON
® is a rapid and immunodiagnostic test that
detects the presence of histidine-rich-protein 2 antigen
(HRP-2) of P. falciparum in whole blood. Positive
results for RDT were confirmed by examining both
thick and thin stained blood smears with light
microscopy.
For peripheral blood, thick blood smears were stained
with 10% Giemsa for ten minutes. For placental blood,
24 hours after collection, pharmacy students prepared
thick placental blood smears and filter paper specimens.
Thick blood smears were air-dried and then stained
with 2% Giemsa for 30 minutes. Experienced microsco-
pists observed the thick blood smears at 100× magnifi-
cation (using immersion oil). The density of P.
falciparum was determined in the peripheral blood by
counting the number of asexual parasites in 200 white
blood cells (WBCs). When estimating parasite density
per μl, a standard WBC concentration of 8,000 WBCs/
μl was assumed. Samples were considered to be negative
when no parasites were found after counting 500 WBC.
Each slide was read by two microscopists blinded to
the other’s readings. A third microscopist settled discre-
pancies between readings. Filter paper specimens were
collected on Whatman 5M filter paper and stored in
individual sterile plastic envelopes containing desiccant.
Parasite density for placental smears was expressed as
the percentage of parasitized red blood cells (RBC)
divided by the total number of RBC, after counting at
least 1,000 RBC.
HIV diagnosis
Umbilical cord blood samples were tested for HIV anti-
bodies with the Determine HIV-1/2 Rapid Test (the
Determine assay; Abbott Laboratories, Abbott Park, Ill.).
Sera reactive by the Determine assay were tested with
the Genie II HIV-1/HIV-2
® test (Bio-Rad, Marnes-La-
Coquette, France), which differentiates between HIV-1
and HIV-2 infections. If the two tests are positive, then
women are considered as infected by HIV. If the first
test is negative, then women are considered HIV-
negative.
Definitions
IPT-SP coverage was defined as the uptake of ≥2d o s e s .
Maternal malaria parasitaemia was defined as a reactive
rapid test confirmed by the presence of asexual parasites
(P. falciparum) in a thick of peripheral cord blood (per-
ipheral malaria) or in a placental smear (placental
malaria). Congenital malaria parasitaemia was defined as
the presence of asexual parasites in peripheral blood
within the first day of life. Low birth weight (LBW) was
defined as birth weight among alive neonates < 2,500
grams and very LBW was defined as < 2,000 grams.
Statistical analysis
Student’s t-test was used to compute medians and inter-
quartile ranges (IQRs) for continuous variables, and the
chi-square test to derive percentages for categorical vari-
ables. Univariable and multivariable logistical regressions
were performed to determine the factors associated with
placental malaria parasitaemia and LBW. For LBW, only
alive singleton infants were included in the analyses. In
the multivariable analysis, the factors associated with the
dependant variable (LBW or placental malaria parasitae-
mia) based on univariable analysis and the known fac-
tors associated with the dependant variable in the
literature were included. Statistical analyses were per-
formed using Stata
® version 10.0 (StataCorp. 2007. Stata
Statistical Software: Release 10. College Station, TX: Sta-
taCorp LP).
Ethics statement
This study was approved by the National Ethics Com-
mittee of Côte d’Ivoire’s Ministry of Health.
Results
Study population
Overall, 2,044 women who gave birth at the six
selected delivery wards were included. Their median
age was 24 years (interquartile range [IQR], 20-30),
and 50.1% of patients were younger than 25 years.
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visits during their pregnancy, and 5.4% (110/2019)
were HIV-infected. The median gravidity was 2 [IQR,
1-4], 533 (26.1%) women were primigravidae, 492
(24.1%) were secundigravidae, and 1,019 (49.8%) were
multigravidae. The median birth weight was 3,000
grams [IQR, 2,700-3,300]. Table 1 describes the char-
acteristics of the study population according to the
number of the IPT-SP dose.
IPT-SP coverage
Of the 2,044 pregnant women, 1,711 women (83.7%)
received ≥1 dose of IPT-SP as prophylaxis against
malaria. The IPT-SP coverage (≥2 doses) was 49.8%
(1017/2044) and varied according to the location of the
study, the number of ANC visits and the other prophy-
l a x i su s e d( T a b l e1 ) .A c c o r d i n gt ot h es t u d yl o c a t i o n ,
the ITP-SP ranged between 24.5% and 67.3% and was
lower in the two districts of Abidjan (the capital city)
Table 1 Description of socio-demographic characteristics of pregnant women in delivery ward according to the
number IPT-SP doses in Côte d’Ivoire (N = 2 044)
IPT-SP dose P Value
Total 0 1 2 ≥3
(N = 2 044) (n = 333) (n = 694) (n = 821) (n = 196)
Age (years)
Median (IQR) 24 (20-30) 25 (20-29) 24 (20-30) 25 (20-30) 24 (20-30) 0.819
<2 0 427 (20.9) 69 (20.7) 155 (22.3) 163 (19.8) 40 (20.4) 0.365
20-24 598 (29.2) 92 (27.5) 201 (29.0) 245 (29.8) 60 (30.6)
25-29 492 (24.1) 96 (28.8) 146 (21.0) 204 (24.9) 46 (23.5)
≥30 527 (25.8) 76 (22.8) 192 (27.7) 209 (25.5) 50 (25.5)
Gravidity
Median (IQR) 2 (1-4) 3 (2-4) 3 (1-4) 2 (1-4) 2 (1-4) 0.120
1 533 (26.1) 79 (23.8) 175 (25.2) 223 (27.2) 56 (28.6) 0.135
2 492 (24.1) 78 (23.4) 167 (24.1) 190 (23.1) 57 (29.1)
≥3 1 019 (49.8) 176 (52.8) 352 (50.7) 408 (49.7) 83 (42.3)
Number of ANC visit < 0.001
Median (IQR) 3 (2-4) 2 (1-3) 2 (1-3) 3 (2-4) 4 (3-5) < 0.001
0 46 (2.2) 41 (12.3) 1 (0.1) 4 (0.5) 0 (0.0)
1-3 1 332 (65.2) 236 (70.9) 570 (83.1) 457 (55.7) 69 (35.2)
≥4 666 (32.6) 56 (16.8) 123 (17.7) 360 (43.8) 127 (64.8)
Birth weight (grams)*
Median (IQR) 3000 (2700-3300) 3000 (2600-3250) 3000 (2650-3250) 3000 (2700-3300) 3000 (2700-3350) 0.942
< 2500 207 (10.6) 35 (11.3) 79 (12.1) 80 (10.1) 13 (6.8) 0.190
< 2000 35 (1.8) 5 (1.6) 13 (2.0) 15 (1.9) 2 (1.0) 0.840
Mothers’HIV status
HIV positive 110 (5.4) 14 (4.2) 42 (6.1) 43 (5.2) 11 (5.6) 0.090
HIV negative 1 914 (93.6) 311 (93.4) 647 (93.2) 771 (93.9) 185 (94.4)
Not collected 20 (1.0) 8 (2.4) 5 (0.7) 7 (0.8) 0 (0.0)
Malaria prophylaxis
Chloroquine 11 (0.5) 11 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) < 0.001
ITNs 980 (47.9) 98 (29.4) 301 (43.4) 532 (64.8) 49 (25.0) < 0.001
Others (insecticide) 272 (13.3) 67 (20.1) 93 (13.4) 73 (8.9) 39 (19.9) < 0.001
Location < 0.001
Koumassi 285 (13.9) 111 (33.3) 104 (15.0) 60 (7.3) 10 (5.1)
Yopougon 400 (19.6) 82 (24.6) 189 (27.2) 113 (13.8) 16 (8.1)
Grand-Lahou 428 (20.9) 35 (10.5) 129 (18.6) 138 (26.8) 126 (64.3)
Sassandra 207 (10.1) 27 (8.1) 67 (9.7) 70 (8.5) 43 (21.9)
San-Pedro 354 (17.3) 27 (8.1) 89 (12.8) 237 (28.9) 1 (0.5)
Bouaké 370 (18.1) 51 (15.3) 116 (16.7) 203 (24.7) 0 (0.0)
IQR: Interquartile range, ANC: Antenatal Care, IPT-SP: Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
*Only for neonates alive (n = 1945)
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0.0001). ITP-SP coverage varied significantly according
to the number of ANC visits (39.5% for 1-3 ANC visits
vs. 73.1% for ≥4 ANC visits; p < 0.0001). No differences
were found according to age, gravidity and mother’s
HIV status (Table 1).
Maternal malaria parasitaemia
Plasmodium falciparum was detected in the peripheral
cord blood of 19 women (0.9%) with a median parasitae-
mia of 164/μl [IQR, 112-540] and in the placenta of 99
women (4.8%) with a median parasitaemia of 780/μl
[IQR, 176-3800] (Table 2). Among the 19 mothers with
peripheral malaria parasitaemia, six (31.6%) did not
receive IPT-SP, seven (36.8%) received one dose and six
(31.6%) received ≥two doses. Among those with placen-
tal malaria parasitaemia (n = 99), 39 (39.4%) did not
receive IPT-SP, 31 (31.3%) received one dose of IPT-SP
and 29 (29.3%) received ≥ two doses.
The factors associated with placental malaria parasi-
taemia in multivariable analysis were: the non-use of
IPT-SP or ITNs during pregnancy, primigravidity, and
antenatal care in Grand-Lahou or Sassandra (Table 3).
A dose effect was found for the association between
IPT-SP and placental malaria parasitaemia. The adjusted
odds ratios (aORs) were 0.18 (95% CI, 0.10-0.32) for
women who received ≥2 doses IPT-SP and 0.32 (95%
CI, 0.19-0.55) for those who received one dose, as com-
p a r e dt ow o m e nw h od i dn o tr eceive IPT-SP. Maternal
HIV infection was not associated with placental malaria
parasitaemia (aOR, 0.25; 95%CI, 0.04-1.42).
When performing this analysis by dividing the variable
of “IPT-SP” into four categories (none, one, two or ≥3
doses), there was a beneficial effect of a third dose: one
dose (aOR = 0.32; 95% CI: 0.19-0.56), two doses (aOR =
0.21 95% CI: 0.12-0.39), and three doses (aOR = 0.12
95% CI: 0.05-0.31), as compared to women who never
received IPT-SP.
Congenital malaria parasitaemia
Blood samples were collected two hours after birth from
85 live neonates born to mothers with placental malaria
parasitaemia. The presence of P. falciparum was
detected among four neonates (4.7%; 95% CI, 1.3-
11.6%): two mothers did not receive IPT-SP, one
received one dose and one mother (25.0%) received ≥ 2
doses. The median parasitaemia value was 186/μl[ I Q R ,
120-514]. All the mothers of infected babies were primi-
gravidae, and none was infected with HIV. The median
age of mothers whose infants had congenital malaria
was lower than that of mothers whose children did not
have congenital malaria (17 years vs. 22 years, p =
0.048).
Low birth weight
Overall, 207 neonates (10.6%) out of 1945 had LBW (<
2,500 grams) and 35 (1.8%) had very low birth weight (<
2,000 grams) (Figure 1). The prevalence of LBW was
Table 2 Prevalence of malaria in pregnant women in antenatal care (N = 2 044)
IPT-SP dose
Total
(N = 2 044)
0
(n = 333)
1
(n = 694)
2
(n = 821)
≥3
(n = 196)
P value
Mothers
Peripheral cord blood positive
Rapid Malaria test (ACON
®) 21 (1.0) 6 (1.8) 8 (1.2) 6 (0.7) 1 (0.5) 0.358
95% Confidence interval [0.64-1.57] [0.66 - 3.88] [0.50-2.26] [0.27-1.58] [0.00-2.81]
Blood smears 19 (0.9) 6 (1.8) 7 (1.0) 6 (0.7) 0 (0.0) 0.564
95% Confidence interval [0.56-1.44] [0.66 - 3.88] [0.41-2.07] [0.27-1.58] [0.00-1.86]
Placental blood positives
Rapid Malaria test (ACON
®) 109 (5.3) 39 (11.7) 34 (4.9) 27 (3.3) 9 (4.6) < 0.001
95% Confidence interval [4.40-6.40] [8.46-15.66] [3.42-6.78] [2.18-4.75] [2.12-8.54]
Blood smears 99 (4.8) 39 (11.7) 31 (4.5) 23 (2.8) 6 (3.1) 0.026
95% Confidence interval [3.95 - 5.86] [8.46-15.66] [3.05-6.28] [1.78 - 4.17] [1.13-6.54]
Neonates
Number of available specimens* 85 35 26 19 5
Peripheral blood positives 4 (4.7) 2 (5.7) 1 (3.8) 1 (5.3) 0 (0.0) 1.00
95 % Confidence interval [1.30-11.61] [0.70-19.16] [0.10-19.64] [0.13-26.03] [0.00-52.18]
* From mothers with placenta blood positive
ε One missing observation
IQR: Interquartile range
IPT-SP: Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
ITNs: insecticide-treated mosquito nets
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among secundigravidae (9.3%) and multigravidae (7.7%)
mothers (p = 0.001). The prevalence of LBW was also
significantly higher among babies born to women with
placental malaria parasitaemia (22.2%) compared to
those born to women without placental malaria parasi-
taemia (10.1%) (p < 0.001).
Figure 1 presents the proportion of neonates with
birth weights < 2,500 grams and < 2,000 grams by
maternal HIV and placental malaria status. The preva-
lence of LBW among neonates born to HIV-uninfected
and malaria-infected women (23.3%) was higher than
among those born to HIV- and malaria-uninfected
women (10.0%) and those born to HIV-infected and
malaria-uninfected women (10.9%) (p = 0.001).
The factors associated with LBW in multivariable ana-
lysis were mother’s age of 20-24 years (aOR = 0.55; 95%
CI, 0.36-0.85), primigravidity (aOR = 2.09; 95% CI, 1.27-
3.43), and placental malaria parasitaemia (aOR = 2.28;
95%CI, 1.32-3.93) (Table 4). Factors not associated with
LBW included maternal HIV infection (aOR = 0.95; 95%
CI, 0.18-5.06).
Discussion
In this study, which was conducted in six antenatal care
facilities in Côte d’Ivoire, the coverage of IPT-SP was
evaluated among 2,044 women giving birth and their
newborns. Overall, only half (49.8%) of the pregnant
women received a complete dose of IPT-SP (≥2d o s e s ) .
The prevalence of placental malaria in mothers was esti-
mated at 4.8% and the prevalence of congenital parasi-
taemia was 4.7% among infants born to mothers with
placental malaria parasitaemia. Factors that protected
the mothers from placental malaria parasitaemia were
the use of IPT-SP or ITNs during pregnancy and multi-
gravidity. The proportion of babies with LBW was
10.6%, with a larger proportion among babies born to
women with placental malaria parasitaemia (22.2%) than
among those born to women without placental malaria
parasitaemia (10.1%).
Table 3 Factors associated with placental malaria: logistic regression model (N = 2 044)
Placental malaria Univariate analysis Multivariate analysis (N = 2 044)
(+)
(n = 99)
(-)
(n = 1 945)
OR 95% CI P value AOR 95% CI P value
Age (years)
< 20 30 (30.3) 397 (20.4) 1 - - 1 - -
20-24 35 (35.3) 563 (29.0) 0.82 [0.50-1.36] 0.448 1.39 [0.78-2.47] 0.261
25-29 17 (17.2) 475 (24.4) 0.47 [0.26-0.87] 0.016 1.10 [0.49-2.48] 0.812
≥30 17 (17.2) 510 (26.2) 0.44 [0.24-0.81] 0.008 1.29 [0.53-3.13] 0.574
Gravidity
1 45 (45.5) 488 (25.1) 2.67 [1.69-4.22] < 0.001 2.96 [1.45-6.04] 0.003
2 20 (20.2) 472 (24.3) 1.23 [0.70-2.15] 0.475 1.18 [0.59-2.33] 0.637
≥3 34 (34.3) 985 (50.6) 1 - - 1 - -
Location
Koumassi 9 (9.1) 276 (14.2) 1 - - 1 - -
Yopougon 13 (13.1) 387 (19.9) 1.03 [0.43-2.44] 0.946 1.43 [0.59-3.47] 0.427
Grand Lahou 25 (25.2) 403 (20.7) 1.90 [1.87-4.14] 0.105 3.01 [1.31-6.92] 0.009
Sassandra 28 (28.3) 179 (9.2) 4.80 [2.21-10.40] < 0.001 8.54 [3.76-19.41] < 0.001
San Pedro 8 (8.1) 346 (17.8) 0.71 [0.27-1.86] 0.485 1.99 [0.70-5.65] 0.198
Bouaké 16 (16.2) 354 (18.2) 1.39 [0.60-3.18] 0.442 2.31 [0.98-5.47] 0.056
Mothers’ HIV status
HIV positive 3 (3.0) 107 (5.5) 0.11 [0.02-0.55] 0.01 0.25 [0.04-1.42] 0.119
HIV negative 92 (92.9) 1 822 (93.7) 0.20 [0.07-0.62] 0.01 0.39 [0.11-1.38] 0.144
Not collected 4 (4.1) 16 (0.8) 1 - - 1 - -
Use of IPT-SP
Yes (≥2 doses) 29 (29.3) 988 (50.8) 0.22 [0.13-0.36] < 0.001 0.18 [0.10-0.32] < 0.001
Yes (1 dose) 31 (31.3) 663 (34.1) 0.35 [0.21-0.58] < 0.001 0.32 [0.19-0.55] < 0.001
No 39 (39.4) 294 (15.1) 1 - - 1 - -
ITNs
Yes 23 (23.2) 957 (49.2) 0.31 [0.19-0.50] < 0.001 0.47 [0.27-0.82] 0.008
No 76 (76.8) 988 (50.8) 1 - - 1 - -
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Page 6 of 10Five years after Côte d’Ivoire adopted and implemen-
ted the 2004 WHO recommendations for the control of
malaria in pregnancies throughout sub-Saharan Africa,
the prevalence of placental malaria parasitaemia was
lower in this study (4.8%) than those reported in recent
African studies in which thisp r e v a l e n c er a n g e df r o m
10.6% to 20.5% [3,6,15]. Comparison between these stu-
dies was difficult. However, several explanations may
explain this difference. First, the study site locations
were different in the two studies. The previous studies
were generally conducted in rural areas [3,6,15] while
this study was conducted in six urban and semi-urban
areas. Second, the characteristics of study population
were different. For example, the proportion of primigra-
vidae was higher in the African studies (ranging from
32.7% to 56.2%) [3,6,15] while it was 26.1% in this study.
Third, the proportion of ITNs use was different; it ran-
ged between 8% and 30% in the previous study, but it
was 48% in this study.
This study clearly showed a dose-effect relation
between IPT-SP use and placental malaria, although the
possible influence of selection biases cannot be excluded
because this study is an observational study. Indeed, a
82% reduction in placental malaria was found among
women who took ≧2 doses of IPT-SP, and a 68%
reduction were found among women who took one
dose, compared to women who did not receive any IPT-
S P .O n l yaf e ws t u d i e sh a v ea l s od e m o n s t r a t e dt h i s
dose-effect relation [16-18]; most of them having
focused on the effectiveness of IPT-SP in preventing
placental malaria parasitaemia in comparison with pla-
cebo [19] or weekly chloroquine chemoprophylaxis
[20,21]. However, IPT-SP coverage in Africa is generally
much lower than the 80% target coverage by 2010, as
proposed in 2000 in Abuja [1,22]. In 2007-2008, the per-
centage of women who received at least two doses of
IPT-SP during pregnancy ranged from 3% to 66% [1]. In
this study, only 49.8% of pregnant women took com-
plete dose (≥two doses). In recent African studies, the
coverage of IPT-SP ranged from 12.5% to 58.8%
[15,17,18]. The operational challenges to delivering ≥2
doses of IPT-SP during pregnancy include staff
shortages, poor drug supplies, poor access to antenatal
care, and improper health worker practices [23-25]. In
this study, only half of the women (53.0%) attended
antenatal care visits at least three times. A similar obser-
vation was found in other African studies in which this
proportion ranged from 45.8% to 58.7% [3,4,15]. There-
fore, strategies, such as free antenatal care, training
health care workers, or providing IPT-SP free of charge
1.5
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Figure 1 Low birth weight (LBW) according to HIV and malaria status in pregnant women in delivery wards in Côte d’Ivoire, 2008-
2009.
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Page 7 of 10and directly observed treatment (DOT), must be imple-
mented or must be encouraged in most African coun-
tries to increase the access to antenatal care and IPT-SP
use as well as other prophylactic methods such as ITNs.
Additional qualitative studies consisting of in-depth
interviews of women as well as health care workers
should be conducted to determine the existing obstacles
to complete IPT-SP coverage.
In this study, the prevalence of congenital malaria was
4.7% among children born to mothers with placental
malaria parasitaemia, and all the cases of congenital
malaria occurred among adolescent and primigravidae
women. A possible explanation for these results is that
the immunity women acquire from a first pregnancy
affected with malaria helps control the subsequent
parasitization of the placenta [26,27]. Generally, the pre-
valence of congenital malaria in a holoendemic area is
globally below 2% and is estimated among all children
without regard to their mother’s status [28-30]. In this
study, infants with congenital malaria were not further
followed to observe if they developed symptoms of
malaria. In one study conducted in Nigeria, among the
95 neonates with congenital malaria, spontaneous clear-
ance of parasitaemia occurred in 62.1% of neonates
before the second day of life and 33.7% were sympto-
matic within three days of birth [29].
The overall prevalence of LBW was 10.6%, with
almost twice as many low-weight babies born to women
with placental malaria parasitaemia (22.2%) compared to
malaria-uninfected women (10.1%). These findings are
Table 4 Factors associated with low birth weight: logistic regression model (N = 1 945)
Low birth weight (grams) Univariate analysis Multivariate analysis
(N = 1938)
Multivariate analysis
(N = 1938)
< 2500 (n = 207) OR 95% CI P value AOR 95% CI P value AOR 95% CI P value
Age (years)
< 20 (n = 407) 76 (18.7) 1 - - 1 - - 1 - -
20-24 (n = 575) 49 (8.5) 0.40 [0.28-0.60] < 0.001 0.55 [0.36-0.85] 0.006 0.58 [0.38-0.89] 0.012
25-29 (n = 469) 44 (9.4) 0.45 [0.30-0.67] < 0.001 0.79 [0.47-1.34] 0.392 0.83 [0.49-1.40] 0.486
> = 30 (n = 494) 38 (7.7) 0.36 [0.24-0.55] < 0.001 0.67 [0.37-1.22] 0.192 0.71 [0.39-1.29] 0.265
Gravidity
1 (n = 509) 89 (17.5) 2.55 [1.83-3.55] < 0.001 2.09 [1.27-3.43] 0.004 2.30 [1.40-3.79] 0.001
2 (n = 471) 44 (9.3) 1.24 [0.84-1.83] 0.279 1.21 [0.77-1.92] 0.407 1.25 [0.79-1.98] 0.332
> = 3 (n = 965) 74 (7.7) 1 - - 1 - - 1 - -
Location
Koumassi (n = 268) 21 (7.8) 1 - - 1 - - 1 - -
Yopougon (n = 388) 50 (12.9) 1.74 [1.02-2.97] 0.043 1.80 [1.03-3.06] 0.037 1.81 [1.05-3.14] 0.033
Grand Lahou (n = 394) 38 (9.6) 1.25 [0.72-2.19] 0.423 1.14 [0.64-2.02] 0.649 1.32 [0.73-2.39] 0.348
Sassandra (n = 187) 23 (12.3) 1.65 [0.88-3.08] 0.116 1.46 [0.77-2.77] 0.244 1.79 [0.94-3.41] 0.077
San Pedro (n = 347) 42 (12.1) 1.62 [0.93-2.81] 0.086 1.58 [0.90-2.77] 0.109 1.79 [1.00-3.22] 0.049
Bouaké (n = 361) 33 (9.1) 1.18 [0.67-2.10] 0.564 1.10 [0.61-1.97] 0.754 1.21 [0.66-2.19] 0.534
Mothers’ HIV status
HIV positive (n = 103) 11 (10.7) 0.66 [0.13-3.36] 0.615 0.95 [0.18-5.06] 0.949 0.86 [0.16-4.64] 0.858
HIV negative (n = 1829) 194 (10.6) 0.65 [0.14-2.10] 0.581 0.80 [0.17-3.81] 0.781 0.74 [0.15-3.57] 0.709
Not collected (n = 13) 2 (15.4) 1 - - 1 - - 1 - -
Malaria status
Positive (n = 90) 20 (22.2) 2.55 [1.52-4.28] < 0.001 2.28 [1.32-3.93] 0.003 - - -
Negative (n = 1855) 187 (10.1) 1 - - 1 - - - - -
Sexe
Male (n = 986) 102 (10.3) 1 - - 1 - - 1 - -
Female (n = 952) 103 (10.8) 1.05 [0.79-1.40] 0.734 1.02 [0.76-1.38] 0.872 1.0 [0.75-1.35] 0.985
Not mentionned (n = 7) 2 (28.6) - - - - - - - - -
Use of IPT-SP
No (n = 310) 35 (11.3) 1 - - - - - 1 - -
1 dose (n = 652) 79 (12.1) 1.08 [0.71-1.65] 0.711 - - - 0.98 [0.63-1.53] 0.935
> = 2 doses (n = 983) 93 (9.5) 0.82 [0.54-1.24] 0.348 - - - 0.71 [0.46-1.12] 0.146
AOR: Adjusted odds ratio; OR: Odds ratio, 95% CI: 95% Confidence interval
IPT-SP: Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
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Page 8 of 10consistent with previous studies that report LBW preva-
lence rates range from 12.4% to 17.3% [6,15,20] and
define placental malaria parasitaemia as a predictor of
LBW [5,7,31]. In this study, IPT-SP was not associated
with a reduction in LBW; however, some studies had
highlighted an association [17,18,32]. A comparison
between this study and others is difficult to make
because the gestational age of women when first dosed
o fI P T - S Pw a sg i v e nw a sn o tc o l l e c t e di nt h i ss t u d ya s
well as other factors that could explain the occurrence
of LBW.
The main strengths of this study were the enrollment
of women in six different districts of Côte d’Ivoire, the
large sample size, and the assessment of malaria parasi-
taemia in both mothers and neonates. This study also
had several limitations. First, the selected health facilities
are only representative of all PMTCT facilities, but may
not be representative of all delivery facilities across Côte
d’Ivoire. The impact of this limitation was reduced by
selecting centers in different regions in Côte d’Ivoire. In
addition, the coverage estimates must be interpreted as
the best-case scenario because only urban and semi-
urban centers were included. Second, because malaria
transmission is endemic throughout the entire region in
Côte d’Ivoire and because the transmission season lasts
7 to 12 months in all of the regions, based on this
study, there is no clear evidence that explains the high
prevalence of placental malaria in the coastal sites in
comparison to other sites (except for their geographical
location). Finally, measurements of the CD4 counts
were not performed for the HIV-infected women. The
impact of the immune status on the LBW was, there-
fore, not evaluated.
Additional studies are needed to evaluate the impact
of increasing resistance to SP [1] and should also focus
on the pharmacokinetics of IPT-SP to determine the
optimal dosing interval for pregnant women [33].
In conclusion, international and national advocacy and
investments in malaria control have increased substan-
tially in recent years, and there is convincing evidence
that, with currently available methods, malaria could
shift from a major public health priority to a fairly
minor burden for already over-stretched health systems.
National health programmes should continue to educate
women on the benefits of receiving antenatal care early
in their pregnancies and of taking a complete course of
IPT-SP. Despite relatively successful IPT-SP coverage in
Côte d’Ivoire, substantial commitments on the part of
national authorities are urgently required for such public
health campaigns. Strategies such as providing IPT-SP
free of charge and DOT should be immediately
established.
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